Last updated: September 8, 2026
Bravelle, the brand name for urofollitropin, was a urinary-derived follicle-stimulating hormone used for ovulation induction and controlled ovarian stimulation. Its U.S. commercial trajectory ended after manufacturing and product-quality problems, including a 2015 recall and subsequent market withdrawal. Bravelle has no meaningful current U.S. revenue base, no active biosimilar opportunity comparable to major biologics, and limited residual patent value. Ferring’s private ownership prevents reliable product-level revenue disclosure.
What is Bravelle and how was it used?
Bravelle contained highly purified urofollitropin, a urinary-derived human follicle-stimulating hormone. The product was administered by subcutaneous or intramuscular injection after reconstitution.
The FDA-approved uses included:
- Induction of ovulation in patients with anovulation who had failed treatment with clomiphene citrate.
- Controlled ovarian stimulation in assisted reproductive technology procedures, including in vitro fertilization.
Bravelle was supplied in single-dose vials, commonly containing 75 international units of follicle-stimulating hormone. Its principal competitors included Menopur, Gonal-f, Follistim AQ, and other gonadotropin products.
| Product |
Active substance |
Origin |
Primary manufacturer or marketer |
| Bravelle |
Urofollitropin |
Urinary-derived |
Ferring Pharmaceuticals |
| Menopur |
Menotropins, containing FSH and LH activity |
Urinary-derived |
Ferring Pharmaceuticals |
| Gonal-f |
Follitropin alfa |
Recombinant |
EMD Serono |
| Follistim AQ |
Follitropin beta |
Recombinant |
Organon |
Urofollitropin differs from recombinant follitropins because it is extracted and purified from postmenopausal human urine. That manufacturing model creates supply, purification, consistency, and quality-control requirements that do not apply in the same form to recombinant products.
When did Bravelle lose commercial exclusivity?
Bravelle lost practical commercial exclusivity through product withdrawal rather than through a major generic launch.
The product was approved under U.S. New Drug Application No. 021448. Any original regulatory exclusivity associated with the approval expired long before the product’s commercial exit. Bravelle’s commercial position was therefore determined by manufacturing continuity, physician familiarity, competing fertility drugs, and Ferring’s portfolio decisions rather than by an intact period of market exclusivity.
Bravelle FDA timeline
| Date or period |
Event |
Commercial significance |
| 2004 |
FDA approval of Bravelle under NDA 021448 |
Established the U.S. branded urofollitropin product |
| 2015 |
Ferring recalled Bravelle lots because of product-quality concerns |
Disrupted supply and reduced prescriber confidence |
| 2016 |
Ferring discontinued U.S. commercial availability |
Removed Bravelle from the active U.S. fertility-drug market |
| Subsequent years |
FDA records treated the product as discontinued, not withdrawn for safety or effectiveness reasons |
Indicates commercial/manufacturing discontinuation rather than an FDA safety ban |
The FDA’s discontinued-drug records are important because they distinguish a commercial withdrawal from a withdrawal based on safety or efficacy. Bravelle’s status was associated with discontinuation and manufacturing issues, not an FDA determination that the approved drug was unsafe or ineffective. [1,2]
What patents protect Bravelle?
Bravelle has limited identifiable residual patent protection in the United States. The principal commercial asset was the approved product and its manufacturing platform, not a current portfolio of blocking patents capable of supporting a new branded market.
The relevant patent categories would have included:
- Composition and purified gonadotropin claims.
- Pharmaceutical formulations and stabilizers.
- Reconstitution and injection methods.
- Manufacturing and purification processes.
- Methods of inducing ovulation or supporting assisted reproduction.
For practical market analysis, those categories carry different value. Broad composition claims for purified urinary-derived FSH would face validity and prior-art constraints. Method-of-use claims in fertility treatment are also difficult to enforce against clinical practice when competing gonadotropins are available. Manufacturing claims can remain commercially relevant, but they generally do not prevent a competitor from using a different purification or production process.
What is the Orange Book status of Bravelle?
Bravelle is not a meaningful current Orange Book blocking asset. Its NDA remains relevant for historical regulatory purposes, but the product is no longer an active commercial reference product in the U.S. market.
There is no current commercial scenario in which a Paragraph IV challenger would need to launch against Bravelle as an active branded product. A generic applicant could theoretically rely on the historical reference product only if FDA’s reference-product and development requirements were satisfied. The absence of active supply would complicate development, sourcing, analytical comparison, and regulatory strategy.
Did Bravelle face Paragraph IV challenges?
There is no widely documented, commercially significant Paragraph IV litigation campaign against Bravelle comparable to those involving high-revenue small-molecule drugs.
The reasons are commercial:
- The addressable market was specialized.
- Bravelle had a short and disrupted commercial life.
- Ferring withdrew the product.
- Competing gonadotropins were already available.
- The product’s urinary-derived manufacturing process created development complexity.
- Potential generic entry would have arrived into a market with established recombinant alternatives.
A Paragraph IV filing would have had limited economic value after the product’s withdrawal. The relevant barrier was not only patent risk. It was the cost of demonstrating pharmaceutical equivalence, securing suitable reference material, reproducing a complex biological purification profile, and obtaining reliable supply.
What caused Bravelle’s commercial decline?
Bravelle’s decline resulted from a combination of quality disruption, competitive substitution, and portfolio economics.
2015 product recall
Ferring recalled Bravelle in 2015 following concerns involving the product’s quality and the potential presence of an impurity or unexpected human chorionic gonadotropin content. The recall damaged supply reliability during fertility-treatment cycles, where treatment continuity is commercially and clinically important. [2]
Competition from Menopur
Ferring’s own Menopur product competed directly with Bravelle in the urinary-derived gonadotropin segment. Menopur contains menotropins with both FSH and LH activity and had a broader role in assisted reproductive treatment. A company-wide portfolio decision could therefore favor Menopur over maintaining a separate urofollitropin product.
Competition from recombinant FSH
Gonal-f and Follistim AQ offered recombinant FSH products supported by established manufacturing platforms and strong fertility-clinic adoption. Recombinant products were generally positioned around batch consistency, supply reliability, and physician familiarity.
Manufacturing economics
Urinary-derived gonadotropins require collection, pooling, purification, viral-risk controls, impurity management, potency testing, and batch-release controls. Those requirements can create higher operational complexity than a recombinant product produced in a controlled cell-based system.
How strong was the Bravelle patent estate?
Bravelle’s current patent estate is commercially weak.
| Patent-value factor |
Assessment |
| Active U.S. product market |
None of material significance |
| Remaining regulatory exclusivity |
None of practical commercial relevance |
| Orange Book blocking value |
Low |
| Formulation patent value |
Limited after discontinuation |
| Method-of-use patent value |
Limited because competing gonadotropins are available |
| Manufacturing know-how |
Potentially relevant, but difficult to monetize without active supply |
| Biosimilar protection |
Not a meaningful current value driver |
| Litigation leverage |
Low |
The most durable intellectual property would likely be proprietary know-how involving purification, impurity control, potency standardization, and process validation. Such know-how may be protected as trade secrets rather than as enforceable product patents. Its value depends on whether the manufacturer continues to operate the relevant production system.
What is the financial trajectory of Bravelle?
Ferring is privately held and does not provide public, audited product-level revenue for Bravelle. No reliable standalone revenue series supports a precise calculation of peak sales, cumulative sales, gross margin, or revenue decline.
The financial trajectory can be established directionally:
| Phase |
Financial profile |
| Launch and early adoption |
Revenue from a differentiated urinary-derived FSH product in fertility clinics |
| Competitive expansion |
Pressure from Menopur and recombinant FSH brands |
| 2015 recall |
Immediate supply disruption, lost prescriptions, remediation expense, and potential inventory write-offs |
| 2016 withdrawal |
Revenue effectively ended in the U.S. |
| Post-withdrawal period |
No material U.S. product revenue; residual value limited to regulatory records, know-how, and possible non-U.S. rights |
Bravelle’s withdrawal eliminated future U.S. revenue but may have reduced ongoing costs associated with manufacturing, quality remediation, distribution, pharmacovigilance, and regulatory maintenance. The net financial effect would depend on recall costs, inventory reserves, contractual obligations, and whether Ferring retained any foreign-market sales.
What was the revenue exposure for Ferring?
Bravelle was strategically relevant to Ferring’s reproductive-medicine portfolio but was unlikely to represent a major group-level revenue driver after the arrival of stronger alternatives and the product-quality disruption. Ferring’s fertility franchise included Menopur and other reproductive-health products, allowing the company to shift commercial activity toward products with stronger supply and market positions.
Because Ferring does not report Bravelle sales separately, the following cannot be determined from public disclosures:
- Peak annual Bravelle revenue.
- Bravelle’s percentage of Ferring revenue.
- U.S. versus international sales.
- Product-level operating margin.
- Recall-related financial charges.
- Revenue transferred to Menopur or other Ferring products.
Any precise revenue figure would be unsupported.
What generic launch risks existed for Bravelle?
A generic launch would have faced four principal risks.
Reference-product availability
A discontinued product creates practical problems for obtaining commercial reference lots, conducting comparative testing, and demonstrating consistent quality.
Complex biological characterization
Urofollitropin is not a simple chemically synthesized molecule. Its activity depends on protein composition, glycosylation, isoform distribution, purity, potency, and impurity controls. A competitor would need to establish a sufficiently comparable product profile.
Manufacturing and supply risk
A generic manufacturer would need reliable access to urinary raw material and a validated purification process. The supply chain would require extensive quality controls and biological-material risk management.
Market-entry economics
Even if regulatory approval were achievable, the product would enter a market with established recombinant FSH products and a limited patient population. Price competition could reduce the return on development investment.
Is Bravelle exposed to biosimilar competition?
Bravelle is not a current biosimilar-risk story.
The product was a urinary-derived gonadotropin and was not positioned like a modern high-revenue recombinant biologic with an active reference product and a developing biosimilar pipeline. A follow-on product would face a complex regulatory and analytical pathway. It could be classified under a generic or biologic framework depending on the product and FDA pathway, but the commercial question is more important: there is no active Bravelle market large enough to attract substantial biosimilar investment.
The competitive threat came from existing alternatives, particularly recombinant follitropins and Menopur, rather than from biosimilar substitution.
What litigation and settlement agreements affected Bravelle?
No major public patent-litigation or settlement event is central to Bravelle’s commercial history. The product’s exit was driven by manufacturing and commercial factors rather than by a high-profile patent settlement.
The absence of significant Paragraph IV litigation is consistent with:
- Limited remaining market value.
- A specialized fertility indication.
- Product discontinuation before a large generic challenge could mature.
- Availability of alternative gonadotropins.
- Limited value in delaying entry into a shrinking or inactive market.
How does Bravelle compare with Menopur, Gonal-f, and Follistim AQ?
| Factor |
Bravelle |
Menopur |
Gonal-f |
Follistim AQ |
| FSH source |
Urinary-derived |
Urinary-derived |
Recombinant |
Recombinant |
| LH activity |
Primarily FSH product |
FSH and LH activity |
FSH-focused |
FSH-focused |
| U.S. commercial status |
Discontinued |
Commercially active historically and in the relevant period |
Commercially active |
Commercially active |
| Manufacturing profile |
Urinary purification |
Urinary purification |
Recombinant cell culture |
Recombinant cell culture |
| Current patent value |
Low |
Product-dependent |
Product-dependent |
Product-dependent |
| Main commercial weakness |
Supply and quality disruption |
Competition and pricing |
Cost and market competition |
Cost and market competition |
| Main Bravelle substitute |
Menopur or recombinant FSH |
Bravelle, recombinant FSH |
Other gonadotropins |
Other gonadotropins |
Bravelle’s closest internal substitute was Menopur. Its broader market substitutes were Gonal-f and Follistim AQ. The shift toward recombinant products reduced the strategic need for a standalone urofollitropin product.
What is the geographic coverage of Bravelle?
Bravelle was primarily relevant to the U.S. fertility market. Its current geographic commercial significance is limited because U.S. sales ended and public sources do not establish a material continuing international franchise.
A country-by-country patent or marketing-rights analysis would require active national registrations, current product catalogs, and local patent records. The available U.S. record supports a conclusion of commercial discontinuation, not an active multinational growth platform.
Key Takeaways
- Bravelle was a urinary-derived urofollitropin product used for ovulation induction and assisted reproduction.
- FDA approval was granted under NDA 021448 in 2004.
- Ferring recalled Bravelle in 2015 after product-quality concerns and discontinued U.S. commercial availability in 2016.
- The product was not withdrawn because FDA found it unsafe or ineffective.
- Bravelle has no meaningful current U.S. patent or Orange Book value.
- No major Paragraph IV litigation or patent settlement drove its market exit.
- Ferring does not disclose product-level Bravelle revenue, so precise financial estimates are unsupported.
- The product’s financial trajectory ended through commercial withdrawal rather than generic erosion.
- Menopur, Gonal-f, and Follistim AQ were the principal competitive alternatives.
- Residual value is concentrated in historical regulatory rights, manufacturing know-how, and any non-U.S. rights that may have survived the U.S. withdrawal.
FAQs
Is Bravelle still available in the United States?
No. Bravelle is no longer commercially available as an active U.S. fertility-treatment product.
Was Bravelle recalled because it caused serious safety problems?
The documented withdrawal was associated with product-quality and manufacturing concerns. FDA records distinguish the discontinuation from a withdrawal for safety or effectiveness reasons.
Can a company launch a generic version of Bravelle?
A company could pursue a follow-on product, but development would face reference-product availability, biological comparability, manufacturing, supply, and limited-market risks.
Did Ferring replace Bravelle with Menopur?
Menopur was the closest Ferring product in the same fertility-treatment portfolio and provided a practical substitute, although the products are not identical and have different hormonal activity profiles.
Does Bravelle have biosimilar competition?
There is no commercially meaningful Bravelle biosimilar market. The principal competitive pressure came from existing urinary-derived and recombinant gonadotropins.
References
- U.S. Food and Drug Administration. (n.d.). Drugs@FDA: Bravelle, NDA 021448.
- U.S. Food and Drug Administration. (n.d.). FDA drug safety and product recall communications concerning Bravelle (urofollitropin for injection).
- U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations.
- Ferring Pharmaceuticals. (2015). Bravelle product recall and product-quality communications.
- U.S. Food and Drug Administration. (n.d.). Approved drug product list and discontinued drug product determinations.
